Current filters:

Rigel Pharmaceuticals

1 to 9 of 12 results

Rigel’s R348 fails to meet endpoints in Ph II dry eye study


Clinical-stage US drug developer Rigel Pharmaceuticals says that R348, its ophthalmic JAK/SYK inhibitor,…

BiotechnologyDry eye diseasefostamatinibOphthalmicsR118R348ResearchRigel Pharmaceuticals

Rigel sees clear forward path for fostamatinib but will drop R333


Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

Rigel Pharma to focus on three leading clinical programs


USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) today announced its plans to focus the company's resources…

DermatologicalsfostamatinibManagementOphthalmicsPharmaceuticalR333R348ResearchRigel Pharmaceuticals

Rigel shares fall as asthma compound fails to meet primary endpoint


Shares of USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) fell 10% to $3.27 in morning trading yesterday…

AstraZenecafostamatinibNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRigel Pharmaceuticals

AstraZeneca returns fostamatinib program rights to Rigel


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Rigel Pharmaceuticals (Nasdaq: RIGL) today…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibLicensingPharmaceuticalResearchRigel Pharmaceuticals

AstraZeneca presents mixed data on fostamatinib in RA


Shares of Anglo-Swedish drug major AstraZeneca (LSE: AZN) fell 2.1% to $47.88 in premarket US trading…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibPharmaceuticalResearchRigel Pharmaceuticals

AstraZeneca gains rights to Rigel's asthma candidate R256


Anglo Swedish drug major AstraZeneca (LSE: AZN) and signed an exclusive global license accord with USA-based…

AstraZenecafostamatinibLicensingPharmaceuticalR256Respiratory and PulmonaryRigel Pharmaceuticals

1 to 9 of 12 results

Back to top